About Cytori Therapeutics (NASDAQ:CYTX)
Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Trailing P/E Ratio-0.42
Forward P/E Ratio-1.53
Sales & Book Value
Annual Sales$2.69 million
Price / Sales6.30
Price / CashN/A
Book Value$0.22 per share
Price / Book1.25
EPS (Most Recent Fiscal Year)($0.65)
Return on Equity-210.47%
Return on Assets-68.94%
Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions
What is Cytori Therapeutics' stock symbol?
Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."
When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?
Cytori Therapeutics's stock reverse split on Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.
How were Cytori Therapeutics' earnings last quarter?
Cytori Therapeutics (NASDAQ:CYTX) issued its earnings results on Thursday, March, 8th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. The biotechnology company earned $1.50 million during the quarter, compared to the consensus estimate of $2 million. Cytori Therapeutics had a negative net margin of 418.36% and a negative return on equity of 210.47%. View Cytori Therapeutics' Earnings History.
When is Cytori Therapeutics' next earnings date?
What price target have analysts set for CYTX?
3 analysts have issued 12-month price targets for Cytori Therapeutics' stock. Their predictions range from $1.65 to $2.30. On average, they expect Cytori Therapeutics' stock price to reach $1.9833 in the next year. View Analyst Ratings for Cytori Therapeutics.
What are Wall Street analysts saying about Cytori Therapeutics stock?
Here are some recent quotes from research analysts about Cytori Therapeutics stock:
- 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (3/8/2018)
- 2. Maxim Group analysts commented, "Cytori presented data in Ovarian Cancer at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting demonstrating bioequivalence of ATI-0918, generic liposomal formulation of doxorubicin, to J&Js CAELYX (branded EU product). We expect Cytori to file for approval in Europe in 2H18 and the company to partner ATI-0918 for commercialization. We profile the opportunity for liposomal doxorubicin, which was acquired with the acquisition of Azaya earlier in 2017, in the attachment below." (11/13/2017)
Who are some of Cytori Therapeutics' key competitors?
Some companies that are related to Cytori Therapeutics include Motus GI (MOTS), SANUWAVE (SNWV), Obalon Therapeutics (OBLN), iCAD (ICAD), Neovasc (NVCN), Spectral Medical (EDTXF), Repro-Med Systems (REPR), Arch Therapeutics (ARTH), Presbia (LENS), Lianluo Smart (LLIT), Cellect Biotechnology (APOP), CAS Medical Systems (CASM), Nephros (NEPH), Pro-Dex (PDEX) and PAVmed (PAVM).
Who are Cytori Therapeutics' key executives?
Cytori Therapeutics' management team includes the folowing people:
- Dr. Marc H. Hedrick M.D., Pres, CEO & Director (Age 55)
- Mr. Tiago M. Girao, VP of Fin., CFO & Principal Accounting Officer (Age 39)
- Mr. John D. Harris, VP & GM of Cell Therapy (Age 49)
- Dr. John K. Fraser Ph.D., Chief Scientist (Age 57)
- Mr. Russ Havranek, VP of Global Marketing
Has Cytori Therapeutics been receiving favorable news coverage?
Headlines about CYTX stock have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cytori Therapeutics earned a daily sentiment score of 0.13 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.98 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Cytori Therapeutics?
Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytori Therapeutics' stock price today?
One share of CYTX stock can currently be purchased for approximately $0.2750.
How big of a company is Cytori Therapeutics?
Cytori Therapeutics has a market capitalization of $17.67 million and generates $2.69 million in revenue each year. The biotechnology company earns $-22,680,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe.
How can I contact Cytori Therapeutics?
Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]
MarketBeat Community Rating for Cytori Therapeutics (CYTX)MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cytori Therapeutics (NASDAQ:CYTX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Cytori Therapeutics (NASDAQ CYTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 6.03%
Cytori Therapeutics (NASDAQ CYTX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/13/2018||Ag Postfinance||Major Shareholder||Sell||286,982||$0.31||$88,964.42||5,118,627|| |
|2/9/2018||Ag Postfinance||Major Shareholder||Sell||236,155||$0.34||$80,292.70||5,311,451|| |
|1/11/2018||Bank Sa Swissquote||Major Shareholder||Sell||72,630||$0.34||$24,694.20||5,496,655|| |
|1/9/2018||Bank Sa Swissquote||Major Shareholder||Sell||100,000||$0.38||$38,000.00||5,496,655|| |
|8/10/2016||John David Harris||VP||Buy||2,500||$2.03||$5,075.00||7,000|| |
|6/14/2016||Gail K Naughton||Director||Buy||1,000||$2.10||$2,100.00||2,400|| |
|5/13/2016||John David Harris||VP||Buy||2,000||$2.71||$5,420.00||2,000|| |
|3/9/2016||David Rickey||Director||Buy||150,000||$0.19||$28,500.00|| |
|9/3/2015||Tommy G Thompson||Director||Buy||25,449||$0.37||$9,416.13|| |
|9/2/2015||Jeremy B Hayden||VP||Buy||8,200||$0.36||$2,952.00||26,200|| |
|8/28/2015||David Rickey||Director||Buy||56,000||$0.31||$17,360.00|| |
|8/28/2015||Marc H Hedrick||CEO||Buy||11,200||$0.31||$3,472.00||504,611|| |
|8/27/2015||David Rickey||Director||Buy||75,000||$0.31||$23,250.00|| |
|8/21/2015||David Rickey||Director||Buy||50,000||$0.38||$19,000.00|| |
|8/21/2015||Marc H Hedrick||CEO||Buy||5,000||$0.38||$1,900.00||504,611|| |
|8/20/2015||Marc H Hedrick||CEO||Buy||10,000||$0.40||$4,000.00||504,611|| |
|8/19/2015||David Rickey||Director||Buy||48,600||$0.39||$18,954.00|| |
|8/19/2015||Steven Kesten||VP||Buy||6,000||$0.39||$2,340.00||2,201|| |
|8/18/2015||David Rickey||Director||Buy||51,400||$0.39||$20,046.00|| |
|8/18/2015||Marc H Hedrick||CEO||Buy||10,000||$0.39||$3,900.00||504,611|| |
|8/18/2015||Tiago Girao||CFO||Buy||25,000||$0.39||$9,750.00||88,000|| |
|11/13/2014||David Rickey||Director||Buy||20,000||$0.47||$9,400.00|| |
|11/12/2014||David Rickey||Director||Buy||200,000||$0.39||$78,000.00|| |
|11/12/2014||Tiago Girao||CFO||Buy||60,000||$0.39||$23,400.00|| |
|11/11/2014||Tiago Girao||CFO||Buy||15,889||$0.39||$6,196.71|| |
|6/5/2014||David Rickey||Director||Buy||30,000||$2.34||$70,200.00|| |
|9/12/2013||David Rickey||Director||Buy||7,100||$2.55||$18,105.00|| |
|9/11/2013||David Rickey||Director||Buy||2,000||$2.58||$5,160.00|| |
|9/9/2013||David Rickey||Director||Buy||5,000||$2.31||$11,550.00|| |
|9/5/2013||David Rickey||Director||Buy||2,000||$2.24||$4,480.00|| |
|9/3/2013||David Rickey||Director||Buy||7,000||$2.14||$14,980.00|| |
|8/30/2013||Tommy G Thompson||Director||Buy||5,000||$2.14||$10,700.00|| |
|12/19/2012||Lloyd H Dean||Director||Buy||25,000||$2.85||$71,250.00|| |
|12/19/2012||Marc H Hedrick||President||Buy||10,000||$2.85||$28,500.00|| |
Cytori Therapeutics (NASDAQ CYTX) News Headlines
Cytori Therapeutics (NASDAQ:CYTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cytori Therapeutics (NASDAQ:CYTX) Income Statement, Balance Sheet and Cash Flow Statement
Cytori Therapeutics (NASDAQ CYTX) Stock Chart for Wednesday, April, 25, 2018